Everything below concerns LY3437943. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-12-11. Numbers and descriptions here follow the published literature rather than marketing material.
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
| Property | Value | Notes |
|---|---|---|
| 研究代号 | LY3437943 | 文献中常用的实验标识 |
| 药物类别 | 三重受体激动剂 | 靶向GLP-1、GIP与胰高血糖素受体 |
| 开发状态 | 后期临床研究 | 尚未获批上市 |
| 主要研究人群 | 肥胖与2型糖尿病 | 入组条件依试验方案而定 |
| 常见同义词 | 瑞他鲁肽；LY3437943 | 名称拼写可能因语言和出版物而异 |
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
The mole (symbol mol) is a unit of measurement, the base unit in the International System of Units (SI) for amount of substance. One mole is an aggregate of exactly 6.02214076×1023 elementary entities which can be atoms, molecules, ions, ion pairs, or other particles. This number of entities equals 602,214,076,000,000,000,000,000, approximately 602 sextillion or 602 billion multiplied by one trillion. The number of particles in a mole is the Avogadro number (symbol N0) and the numerical value of the Avogadro constant (symbol NA) has units of mol−1. The relationship between the mole, Avogadro number, and Avogadro constant can be expressed in the following equation:
Pegcetacoplan, sold under the brand name Empaveli among others, is a medication used to treat paroxysmal nocturnal hemoglobinuria, geographic atrophy of the retina, glomerulopathy C3 and membranoproliferative globulonephritis. Pegcetacoplan is a complement inhibitor. The most common side effects include injection-site reactions, infections, diarrhea, abdominal pain, respiratory tract infection, viral infection, and fatigue. Paroxysmal nocturnal hemoglobinuria is characterized by red blood cell destruction, anemia (red blood cells unable to carry enough oxygen to tissues), blood clots, and impaired bone marrow function (not making enough blood cells). Pegcetacoplan is the first treatment for paroxysmal nocturnal hemoglobinuria that binds to and inhibits complement protein C3. Pegcetacoplan was approved for medical use in the United States in May 2021. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication. In 2024, the American Society of Nephrology Annual Kidney Meeting, the study group who investigating pegcetacoplan in the largest multicenter double-blind VALIANT trial, showed its significant benefits in the treatment of patients with C3 glomerulopathy or primary immune complex–mediated membranoproliferative glomerulonephritis. C3 glomerulopathy leads to kidney failure in approximately 50% of patients within 5–10 years of diagnosis, and even when patients do receive a kidney transplant, approximately two thirds experience disease recurrence.
=== Environmental aspects === Silk is often held up as a prime example of green chemistry in materials science, and the argument is not without merit. Fibroin can be purified and processed largely in water, avoiding the organic solvents and high temperatures typically required for synthetic polymers, and the protein itself is renewable and biodegradable. The recovery of both fibroin and sericin from silk and textile industries turns waste and by-products into feedstock. Benefits like these have to be weighed against the resource needs of silk farming and the energy involved in degumming and purification.
== History and operations == The company is owned, with a majority share, by Hero Brands, based in Glasgow, Scotland, which also owns Hawaiian food brand Island Poké and salad restaurant Choppaluna. As of January 2024, the chain operates in six countries; the United Kingdom, United Arab Emirates, Sweden, Canada, United States, and Saudi Arabia. The company claims to trace its heritage to a restaurant in Berlin, Germany in 1989. It developed its offering over the following decade, until Farshad Abbaszadeh launched the first "Doner Kebab" franchise in Dubai in 2013. It then opened its first UK restaurant in 2015, expanding to seven by the end of 2017. In 2014, the franchise won the award "Best UAE Franchise Brand" at the 2014 MENAFA Excellence awards in Dubai. In 2016, while on holiday in Dubai, Athif Sarwar, came across the franchise and was later granted development rights to the franchise in the UK. Sarwar later purchased the international rights to the brand from Farshad Abbaszadeh, CEO and Founder of German Doner Kebab. The chain was then bought by the Sarwar Family in 2017, which moved its headquarters to Glasgow, Scotland, in the United Kingdom. In July 2022, Imran Sayeed, chief executive, expressed his desire for the company to be made public and listed on the New York Stock Exchange in the following three to five years, as the chain sees North America as its "next growth engine". In March 2023, Simon Wallis was appointed chief executive replacing Imran Sayeed, with Robin Caley as chief development officer.
Sources: en.wikipedia.org
The reaction happens with two metal cofactors (Mg or Mn) coordinated to the two aspartate residues on C1. They perform a nucleophilic attack of the 3'-OH group of the ribose on the α-phosphoryl group of ATP. The two lysine and aspartate residues on C2 selects ATP over GTP for the substrate, so that the enzyme is not a guanylyl cyclase. A pair of arginine and asparagine residues on C2 stabilizes the transition state. In many proteins, these residues are nevertheless mutated while retaining the adenylyl cyclase activity. There are ten known isoforms of adenylyl cyclases in mammals: These are also sometimes called simply AC1, AC2, etc., and, somewhat confusingly, sometimes Roman numerals are used for these isoforms that all belong to the overall AC class III. They differ mainly in how they are regulated, and are differentially expressed in various tissues throughout mammalian development.
Schering AG filed for a patent for NETA in June 1957, and the patent was issued in December 1960. The drug was first marketed, by Parke-Davis as Norlestrin in the United States, in March 1964. This was a combination formulation of 2.5 mg NETA and 50 μg ethinylestradiol and was indicated as an oral contraceptive. Other early brand names of NETA used in oral contraceptives included Minovlar and Anovlar. Norethisterone acetate is the INNTooltip International Nonproprietary Name, BANMTooltip British Approved Name, and JANTooltip Japanese Accepted Name of NETA while norethindrone acetate is its USANTooltip United States Adopted Name and USPTooltip United States Pharmacopeia. NETA is marketed under a variety of brand names throughout the world including Primolut-Nor (major), Aygestin (USTooltip United States), Gestakadin, Milligynon, Monogest, Norlutate (USTooltip United States, CATooltip Canada), Primolut N, SH-420 (UKTooltip United Kingdom), Sovel, and Styptin among others.
Rubidium (37Rb) has 35 known isotopes, from 72Rb to 106Rb, with naturally occurring rubidium composed of two: stable 85Rb (72.2%) and radioactive 87Rb (27.8%). The primordial radionuclide 87Rb has a half-life of 4.97×1010 years, beta decaying to stable 87Sr. It is, as the element is, widespread on Earth as rubidium readily substitutes for potassium in all minerals. The decay of 87Rb has been used extensively in dating rocks; see rubidium–strontium dating for a more detailed discussion. Other than 87Rb, the longest-lived radioisotopes are 83Rb with a half-life of 86.2 days, 84Rb with a half-life of 32.82 days, and 86Rb with a half-life of 18.645 days. All other radioisotopes have half-lives less than a day, most less than 20 minutes. Of the isomeric states the most stable is 82mRb at 6.472 hours. The ground state of 82Rb has a much shorter half-life of 1.2575 minutes. It is used medically in some cardiac positron emission tomography scans to assess myocardial perfusion. It is synthesized through the longer-lived 82Sr, made in a cyclotron, though a generator. It may be administered as the chloride.
== History == Insulin degludec has been filed for registration in the United States. After the completion of additional cardiac safety studies requested by the US Food and Drug Administration (FDA) in February 2013, it received FDA approval in September 2015 and marketing began in January 2016.
=== Adoption in precolonial scholarship === The earliest attempt to associate the people of the Gold Coast with ancient Ghana had been made by Rev. J. B. Anaman around the turn of the 20th century. Anaman drew on W.D. Cooley's 19th-century interpretation of Arabic geographical sources to make an argument for a historical connection, suggesting an alternative derivation connecting the name to the Wangara people. Lady Flora Shaw later compiled both Arabic and European writings to create detailed narratives of the kingdom. She presented it as a major African power comparable to contemporary Western European states. According to Jack Goody, the theory that the Akan peoples originated from the medieval Empire of Ghana was continuously promoted through the teachings of Rev. W. T. Balmer between 1907 and 1911, who instructed students that the Akan had migrated from the ancient kingdom located near the Upper Niger. Goody states that Balmer's hypothesis lacked linguistic and historical evidence, yet it later became influential among educated elites and nationalist intellectuals. The hypothesis gained more popularity when it was introduced into educational institutions, primarily in Achimota, during the 1920s where it later spread to other schools. The theory was later publicized by J. B. Danquah's academic writings; he used Arabic and French translations to claim that the Akan migrated from the Upper Niger region. Danquah proposed that the term Ghana was a corruption of Akane or Akana and associated it with the ancient region of Akkad. Eva L. R.
Sources: en.wikipedia.org
尚未。它仍处于临床研究阶段，任何监管批准都取决于正在进行的试验结果和提交审评。可公开获取的信息以试验注册和会议摘要为主。
司美格鲁肽主要靶向GLP-1受体，而瑞他鲁肽同时作用于GLP-1、GIP和胰高血糖素受体。这种三重机制旨在产生不同的代谢效应，但临床差异仍需头对头研究确认。
长期心血管结局、停药后维持效果、罕见不良事件和不同人群中的获益风险比尚未完全确定。完整三期数据和监管审评将影响结论。
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.